AstraZeneca (AZN)
(Delayed Data from NSDQ)
$78.02 USD
+1.25 (1.63%)
Updated May 31, 2024 04:00 PM ET
After-Market: $78.29 +0.27 (0.35%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AZN 78.02 +1.25(1.63%)
Will AZN be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for AZN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AZN
Pfizer (PFE) Up 1.8% Since Last Earnings Report: Can It Continue?
Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
AZN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Roche's (RHHBY) Inavolisib NDA Gets FDA Priority Review Tag
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
Other News for AZN
Stocks Seeing Relentless Buying Pressure; Bonds Are Not
SA Asks: Which weight-loss stocks should investors be watching?
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy